Novavax Inc (NVAX) stock
Close on Nov 17, 2026Market cap $1.31BP/E –Yield –
Earnings
Novavax's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Novavax's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | $68.00M | -2.9% | -$0.19 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | $57.00M | -76.2% | -$0.32 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026before the open | $140.00M | -79.0% | -$0.06 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026before the open | $147.00M | +67.0% | $0.11 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | $70.00M | -17.6% | -$1.25 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025before the open | $239.00M | -42.4% | $0.62 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | $667.00M | +609.6% | $2.93 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025before the open | $88.00M | -69.8% | -$0.51 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | $85.00M | -54.5% | -$0.76 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | $415.00M | -2.1% | $0.99 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 10, 2024before the open | $94.00M | +16.0% | -$1.05 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024before the open | $291.00M | -18.5% | -$1.44 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023before the open | $187.00M | -74.6% | -$1.26 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023before the open | $424.00M | +128.0% | $0.58 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023before the open | $81.00M | -88.5% | -$3.41 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023after the close | $357.00M | +60.8% | -$2.28 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022after the close | $735.00M | +311.1% | -$2.15 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022after the close | $186.00M | – | -$6.53 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022after the close | $704.00M | – | $2.56 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 1, 2022after the close | $222.00M | – | -$11.18 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 5, 2021after the close | $178.80M | – | -$4.31 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 6, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 11, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 2, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 10, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Novavax's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Adjusted Total Revenuenon-GAAP | FY2026 | $385.00M – $415.00M | $230.00M – $270.00M | Raised | Nov 5, 2026 |
| Adjusted Total Revenuenon-GAAP | FY2026 | $235.00M – $275.00M | $230.00M – $270.00M | Raised | Aug 6, 2026 |
| Nuvaxovid Product Sales | FY2026 | $35.00M – $45.00M | $40.00M – $50.00M | Lowered | Aug 6, 2026 |
| combined R&D and SG&A expenses | FY2026 | $350.00M | – | New | Nov 12, 2024 |
| Combined R&D and SG&A ExpensesGAAP | FY2026 | $375.00M – $395.00M | $380.00M – $420.00M | Lowered | Nov 5, 2026 |
| Combined R&D and SG&A ExpensesGAAP | FY2026 | $370.00M – $410.00M | – | New | Aug 6, 2026 |
| Combined R&D and SG&A Expenses | FY2026 | $380.00M – $420.00M | – | New | May 6, 2026 |
| Less: R&D Reimbursements | FY2026 | -$80.00M – -$70.00M | – | Lowered | May 6, 2026 |
| Non-GAAP combined R&D and Selling, General and Administrative (SG&A) expensesnon-GAAP | FY2026 | $325.00M | – | New | May 6, 2026 |
| Non-GAAP Combined R&D and SG&A Expensesnon-GAAP | FY2026 | $315.00M – $335.00M | $310.00M – $340.00M | Narrowed | Nov 5, 2026 |
| Non-GAAP Combined R&D and SG&A Expensesnon-GAAP | FY2026 | $310.00M – $340.00M | $310.00M – $340.00M | Reaffirmed | Aug 6, 2026 |
| Combined R&D and SG&A Expenses, Net of Partner Reimbursementnon-GAAP | FY2027 | $250.00M | – | New | Jan 12, 2026 |
| Non-GAAP combined R&D and Selling, General and Administrative (SG&A) expensesnon-GAAP | FY2027 | $225.00M | – | Lowered | May 6, 2026 |
| Non-GAAP combined R&D and SG&A expensesnon-GAAP | FY2028 | $150.00M – $200.00M | – | New | May 6, 2026 |
Guidance vs results
The last range Novavax gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $35.00M – $45.00M | $1.12BΣ4Q | Above range |
| Q1 FY2024 | Revenue | $100.00M | $94.00M | Below range |
Guidance history
Every forecast Novavax put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | Non-GAAP Combined R&D and SG&A Expenses | FY2026 | $315.00M – $335.00M | Narrowed |
| Nov 5, 2026 | Combined R&D and SG&A Expenses | FY2026 | $375.00M – $395.00M | Lowered |
| Nov 5, 2026 | Adjusted Total Revenue | FY2026 | $385.00M – $415.00M | Raised |
| Aug 6, 2026 | Combined R&D and SG&A Expenses | FY2026 | $370.00M – $410.00M | New |
| Aug 6, 2026 | Non-GAAP Combined R&D and SG&A Expenses | FY2026 | $310.00M – $340.00M | Reaffirmed |
| Aug 6, 2026 | Adjusted Total Revenue | FY2026 | $235.00M – $275.00M | Raised |
| Aug 6, 2026 | Nuvaxovid Product Sales | FY2026 | $35.00M – $45.00M | Lowered |
| Aug 6, 2026 | Adjusted Licensing, Royalties and Other Revenue | FY2026 | $155.00M – $175.00M | Raised |
| Aug 6, 2026 | Adjusted Supply Sales | FY2026 | $45.00M – $55.00M | Lowered |
| May 6, 2026 | Non-GAAP combined R&D and Selling, General and Administrative (SG&A) expenses | FY2026 | $325.00M | New |
| May 6, 2026 | Non-GAAP combined R&D and SG&A expenses | FY2028 | $150.00M – $200.00M | New |
| May 6, 2026 | Non-GAAP combined R&D and Selling, General and Administrative (SG&A) expenses | FY2027 | $225.00M | Lowered |
| May 6, 2026 | Combined R&D and SG&A Expenses | FY2026 | $380.00M – $420.00M | New |
| May 6, 2026 | Less: R&D Reimbursements | FY2026 | -$80.00M – -$70.00M | Lowered |
| May 6, 2026 | Non-GAAP Combined R&D and SG&A Expenses | FY2026 | $310.00M – $340.00M | Reaffirmed |
| May 6, 2026 | Adjusted Supply Sales | FY2026 | $40.00M – $50.00M | Raised |
| May 6, 2026 | Nuvaxovid Product Sa les | FY2026 | $35.00M – $45.00M | New |
| May 6, 2026 | Adjusted Total Revenue | FY2026 | $230.00M – $270.00M | New |
| May 6, 2026 | Adjusted Licensing, Royalties and Other Revenue | FY2026 | $155.00M – $175.00M | Raised |
| Feb 26, 2026 | Non-GAAP Combined R&D and SG&A Expenses | FY2026 | $310.00M – $340.00M | New |
| Feb 26, 2026 | Combined R&D and SG&A Expenses | FY2026 | $380.00M – $420.00M | New |
| Feb 26, 2026 | Adjusted Total Revenue | FY2026 | $230.00M – $270.00M | New |
| Jan 12, 2026 | Combined R&D and SG&A Expenses, Net of Partner Reimbursement | FY2027 | $250.00M | New |
| Nov 6, 2025 | Non-GAAP Combined R&D and SG&A Expenses | FY2025 | $440.00M – $460.00M | New |
| Nov 6, 2025 | R&D Reimbursements | FY2025 | $65.00M – $75.00M | New |
| Nov 6, 2025 | Combined R&D and SG&A Expenses | FY2025 | $505.00M – $535.00M | New |
| Nov 6, 2025 | Adjusted Supply Sales | FY2025 | $35.00M – $45.00M | Lowered |
| Nov 6, 2025 | Adjusted Total Revenue | FY2025 | $1.04B – $1.06B | Raised |
| Nov 6, 2025 | Adjusted Licensing, Royalties and Other Revenue | FY2025 | $395.00M – $405.00M | New |
| Nov 6, 2025 | Nuvaxovid Product Sales | FY2025 | $610.00M | New |
| Aug 6, 2025 | Combined R&D and SG&A Expenses | FY2025 | $495.00M – $545.00M | Raised |
| Aug 6, 2025 | Adjusted Licensing, Royalties and Other Revenue | FY2025 | $365.00M – $400.00M | Raised |
| Aug 6, 2025 | Nuvaxovid Product Sales | FY2025 | $610.00M | Raised |
| Aug 6, 2025 | Adjusted Total Revenue | FY2025 | $1.00B – $1.05B | Raised |
| Aug 6, 2025 | Adjusted Supply Sales | FY2025 | $25.00M – $40.00M | Lowered |
| May 8, 2025 | combined R&D and SG&A expenses | FY2025 | $475.00M – $525.00M | Reaffirmed |
| May 8, 2025 | Adjusted Supply Sales | FY2025 | $20.00M – $35.00M | Lowered |
| May 8, 2025 | Nuvaxovid Product Sales | FY2025 | $610.00M | New |
| May 8, 2025 | Adjusted Total Revenue | FY2025 | $975.00M – $1.03B | Raised |
| May 8, 2025 | Adjusted Licensing, Royalties and Other Revenue | FY2025 | $345.00M – $380.00M | Lowered |
| Feb 27, 2025 | Combined R&D and SG&A Expenses | FY2025 | $475.00M – $525.00M | Reaffirmed |
| Feb 27, 2025 | Adjusted Licensing, Royalties and Other Revenue | FY2025 | $300.00M – $350.00M | New |
| Jan 13, 2025 | Combined Annual R&D and SG&A Expense, net of expected $50M reimbursement | FY2025 | $450.00M | New |
| Jan 13, 2025 | Combined R&D and SG&A | FY2024 | $700.00M – $750.00M | Reaffirmed |
| Jan 13, 2025 | Total Revenue | FY2024 | $650.00M – $700.00M | Raised |
| Jan 13, 2025 | Licensing, Royalties and Other Revenue | FY2024 | $475.00M | Raised |
| Jan 13, 2025 | Product Sales | FY2024 | $175.00M – $225.00M | Lowered |
| Nov 12, 2024 | combined R&D and SG&A expenses | FY2026 | $350.00M | New |
| Nov 12, 2024 | Combined R&D and SG&A | FY2024 | $700.00M – $750.00M | Reaffirmed |
| Nov 12, 2024 | combined R&D and SG&A expenses | FY2025 | $500.00M | New |
| Nov 12, 2024 | Licensing, Royalties and Other Revenue | FY2024 | $475.00M | Raised |
| Nov 12, 2024 | Product Sales | FY2024 | $175.00M – $225.00M | Lowered |
| Nov 12, 2024 | Total Revenue | FY2024 | $650.00M – $700.00M | Lowered |
| Aug 8, 2024 | Combined R&D and SG&A | FY2024 | $700.00M – $750.00M | Reaffirmed |
| Aug 8, 2024 | Total Revenue | FY2024 | $700.00M – $800.00M | Raised |
| May 10, 2024 | Combined R&D and SG&A | FY2024 | $700.00M – $750.00M | Raised |
| May 10, 2024 | Initial Sanofi Agreement Payments | FY2024 | $570.00M | Lowered |
| May 10, 2024 | Total Revenue | FY2024 | $400.00M – $600.00M | Lowered |
| May 10, 2024 | Combined Revenue and Sanofi Agreement Payments | FY2024 | $970.00M – $1.17B | Raised |
| Feb 28, 2024 | Combined R&D and SG&A | FY2024 | $700.00M – $800.00M | New |
| Feb 28, 2024 | Total Revenue | FY2024 | $800.00M – $1.00B | New |
| Feb 28, 2024 | Total Revenue | Q1 FY2024 | $100.00M | Lowered |
| Nov 9, 2023 | Combined R&D and SG&A | FY2023 | $1.15B – $1.25B | Lowered |
| Nov 9, 2023 | Grants, royalties & other | Combined FY 2023 & Q1 2024 | $450.00M | – |
| Nov 9, 2023 | Grants, royalties & other | FY2023 | $425.00M – $475.00M | Lowered |
| Nov 9, 2023 | Total Revenue | FY2023 | $900.00M – $1.10B | Lowered |
| Nov 9, 2023 | Total Revenue | Combined FY 2023 & Q1 2024 | $1.30B | – |
| Nov 9, 2023 | Product Sales | Combined FY 2023 & Q1 2024 | $850.00M | – |
| Nov 9, 2023 | Product Sales | Q1 FY2024 | $300.00M | Reaffirmed |
| Nov 9, 2023 | Total Revenue | Q1 FY2024 | $300.00M | New |
| Nov 9, 2023 | Product Sales | FY2023 | $475.00M – $625.00M | Lowered |
| Aug 8, 2023 | Combined R&D and SG&A | FY2023 | $1.30B – $1.40B | New |
| Aug 8, 2023 | Product Sales | FY2023 | $960.00M – $1.14B | Raised |
| Aug 8, 2023 | Grant Revenue | FY2023 | $340.00M – $360.00M | Lowered |
| Aug 8, 2023 | Total Revenue | FY2023 | $1.30B – $1.50B | Lowered |
| May 9, 2023 | Combined R&D and SG&A expenses | FY2023 | $1.30B – $1.40B | New |
| May 9, 2023 | total revenue | FY2023 | $1.40B – $1.60B | New |
| Nov 8, 2022 | total revenue guidance | FY2022 | $2.00B | Lowered |
| Aug 9, 2022 | total revenue guidance | FY2022 | $2.00B – $2.30B | Lowered |
| May 10, 2022 | total revenue | FY2022 | $4.00B – $5.00B | Reaffirmed |
| Mar 1, 2022 | total revenue | FY2022 | $4.00B – $5.00B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Novavax filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Update
- Update
- Update
- News
- Results
- Update
- Update
- Results
See a number that looks wrong?